Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study.

Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One (2012) 3.68

Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med (2015) 1.11

Prevalence and determinants of electrocardiographic abnormalities in African Americans with type 2 diabetes. J Epidemiol Glob Health (2014) 0.95

Electrocardiographic spatial QRS-T angle and incident cardiovascular disease in HIV-infected patients (from the Strategies for the Management of Antiretroviral Therapy [SMART] study). Am J Cardiol (2012) 0.81

Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infection. Am J Cardiol (2012) 0.77

Protease inhibitors and cardiac autonomic function in HIV-infected patients: a cross-sectional analysis from the Strategies for Management of Antiretroviral Therapy (SMART) Trial. BMJ Open (2013) 0.77

Progression of Electrocardiographic Abnormalities in Type 1 Diabetes During 16 Years of Follow-up: The Epidemiology of Diabetes Interventions and Complications (EDIC) Study. J Am Heart Assoc (2016) 0.75

Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: results from the Strategies for Management of Antiretroviral Therapy [SMART] Study. J Electrocardiol (2013) 0.75

Usefulness of Maintaining a Normal Electrocardiogram Over Time for Predicting Cardiovascular Health. Am J Cardiol (2016) 0.75

CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76

Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93

Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23

Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab (2007) 9.77

Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med (2003) 5.88

Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr (2003) 4.64

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial. Ann Intern Med (2008) 3.68

Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis (2007) 2.69

Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation (2008) 2.64

Electrocardiographic findings in a healthy biracial population. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Cardiol (1998) 2.31

Association of nonspecific minor ST-T abnormalities with cardiovascular mortality: the Chicago Western Electric Study. JAMA (1999) 2.00

Electrocardiographic abnormalities and 30-year mortality among white and black men of the Charleston Heart Study. Circulation (1993) 1.67

Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials (2008) 1.65

Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med (2005) 1.49

Impact of minor electrocardiographic ST-segment and/or T-wave abnormalities on cardiovascular mortality during long-term follow-up. Am J Cardiol (2003) 1.42

Prevalences of ECG findings in large population based samples of men and women. Heart (2000) 1.40

Prognostic associations of Minnesota Code serial electrocardiographic change classification with coronary heart disease mortality in the Multiple Risk Factor Intervention Trial. Am J Cardiol (1997) 1.29

Electrocardiographic abnormalities and mortality among middle-aged black men and white men of Evans County, Georgia. J Chronic Dis (1987) 1.27

Major and minor electrocardiographic abnormalities and risk of death from coronary heart disease, cardiovascular diseases and all causes in men and women. J Am Coll Cardiol (1988) 1.25

Subclinical coronary atherosclerosis and resting ECG abnormalities in an unselected general population. Atherosclerosis (2007) 1.02

Prevalence and risk factors of prolonged QTc interval in HIV-infected patients: results of the HIV-HEART study. HIV Clin Trials (2009) 1.01

The predictive value of electrocardiographic abnormalities for total and cardiovascular disease mortality in men and women. Eur Heart J (1994) 1.01

Asymptomatic myocardial ischaemia in HIV-infected adults. AIDS (2008) 1.00

Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study. Br J Clin Pharmacol (2008) 0.97

Association of electrocardiographic abnormalities with coronary artery calcium and carotid artery intima-media thickness in individuals without clinical coronary heart disease (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol (2009) 0.89

Prevalences and correlates of ECG abnormalities in the adult Belgian population. J Electrocardiol (1995) 0.81

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72

The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology (2005) 13.05

Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93

Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23

Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (2008) 8.73

Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet (2008) 7.70

Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41

Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA (2003) 7.35

The prevention and treatment of missing data in clinical trials. N Engl J Med (2012) 6.92

Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation (2003) 6.47

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 5.61

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation (2009) 5.49

Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis (2010) 5.35

CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS (2008) 5.30

Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. Crit Care Med (2011) 5.28

Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet (2009) 5.23

Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J (2009) 4.90

American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr (2004) 4.88

ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography). Circulation (2007) 4.66

AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation (2011) 4.65

Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr (2003) 4.64

Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med (2003) 4.59

Stop Hypertension with the Acupuncture Research Program (SHARP): results of a randomized, controlled clinical trial. Hypertension (2006) 4.54

Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS (2005) 4.40

Ethnic distribution of ECG predictors of atrial fibrillation and its impact on understanding the ethnic distribution of ischemic stroke in the Atherosclerosis Risk in Communities (ARIC) study. Stroke (2009) 4.21

Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet (2009) 4.10

Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA (2009) 3.83

Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA (2003) 3.71

Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One (2012) 3.68

Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care (2008) 3.65

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet (2004) 3.59

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59

Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol (2006) 3.51

Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS (2010) 3.47

The role of HIV in serious diseases other than AIDS. AIDS (2008) 3.39

Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol (2008) 3.36

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis (2008) 3.35

Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2008) 3.15

Projected life expectancy of people with HIV according to timing of diagnosis. AIDS (2012) 3.09

Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis (2003) 3.07

Association of race and sex with risk of incident acute coronary heart disease events. JAMA (2012) 3.07

Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. J Infect Dis (2013) 3.04

Pulse pressure and cardiovascular disease-related mortality: follow-up study of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA (2002) 2.96

Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. Antivir Ther (2008) 2.93

Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis (2011) 2.88

Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis (2011) 2.86

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS (2010) 2.85

Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis (2013) 2.82

Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation (2007) 2.82

Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med (2005) 2.80

All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80

Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr (2014) 2.79

Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials (2012) 2.71

Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70

Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis (2004) 2.70

Estimated 10-year stroke risk by region and race in the United States: geographic and racial differences in stroke risk. Ann Neurol (2008) 2.68

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2008) 2.67

Arterial wave reflections and incident cardiovascular events and heart failure: MESA (Multiethnic Study of Atherosclerosis). J Am Coll Cardiol (2012) 2.65

Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation (2008) 2.64

Invasive Candida infections and the harm from antibacterial drugs in critically ill patients: data from a randomized, controlled trial to determine the role of ciprofloxacin, piperacillin-tazobactam, meropenem, and cefuroxime. Crit Care Med (2015) 2.62

Genetic variations in nitric oxide synthase 1 adaptor protein are associated with sudden cardiac death in US white community-based populations. Circulation (2009) 2.55

Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med (2013) 2.49

AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol (2011) 2.45

Improving Diabetes Care in Practice: findings from the TRANSLATE trial. Diabetes Care (2008) 2.42

Does detection of carotid plaque affect physician behavior or motivate patients? Am Heart J (2007) 2.33

Long-term cardiovascular mortality among middle-aged men with gout. Arch Intern Med (2008) 2.32

HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS (2008) 2.27

Prospective study of particulate air pollution exposures, subclinical atherosclerosis, and clinical cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis and Air Pollution (MESA Air). Am J Epidemiol (2012) 2.23

Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr (2011) 2.21

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis (2009) 2.20

State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation (2008) 2.17

Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med (2010) 2.17

Hypertension, blood pressure, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. Hypertension (2003) 2.12

Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. AIDS (2013) 2.11

Trends of elevated blood pressure among children and adolescents: data from the National Health and Nutrition Examination Survey1988-2006. Am J Hypertens (2008) 2.10

Monitoring the quality of conduct of clinical trials: a survey of current practices. Clin Trials (2011) 2.08

Chronic renal failure among HIV-1-infected patients. AIDS (2007) 2.07

Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis (2008) 2.06

Methodological issues in cohort studies that relate sodium intake to cardiovascular disease outcomes: a science advisory from the American Heart Association. Circulation (2014) 2.05

Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS (2010) 2.03

Race/ethnicity, income, major risk factors, and cardiovascular disease mortality. Am J Public Health (2005) 2.02

Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease. AIDS (2014) 2.02

Prospective evaluation of a whole-blood test using Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 for diagnosis of active tuberculosis. Clin Diagn Lab Immunol (2005) 2.02

Dietary fish and omega-3 fatty acid consumption and heart rate variability in US adults. Circulation (2008) 2.02

Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). Circulation (2009) 2.01

National Health and Nutrition Examination Survey 1999-2000: effect of observer training and protocol standardization on reducing blood pressure measurement error. J Clin Epidemiol (2003) 2.00

Effects of continuous aortic flow augmentation in patients with exacerbation of heart failure inadequately responsive to medical therapy: results of the Multicenter Trial of the Orqis Medical Cancion System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). Circulation (2008) 2.00

When should antiretroviral therapy for HIV be started? BMJ (2007) 1.95

Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population. AIDS (2010) 1.93